Lake Forest, IL, April 20, 2011 – Actient Pharmaceuticals LLC (“Actient”) announced today that it has acquired the U.S. rights to Striant® (testosterone buccal system) from Columbia Laboratories, Inc. Striant utilizes a novel mucoadhesive technology that allows for oral administration of testosterone using buccal absorption. Striant is the only testosterone replacement therapy that features this unique delivery option.
The acquisition of Striant is consistent with Actient’s strategic focus in urology. Actient currently markets leading products for the treatment of urological disorders, including Edex® (alprostadil for injection) and Osbon ErecAid®, both promoted by Timm Medical Technologies, Actient’s wholly-owned subsidiary.
“Striant offers physicians and their patients an important alternative for testosterone replacement therapy,” said Ed Fiorentino, CEO of Actient. “We look forward to adding Striant to our expanding urology portfolio so that we can more broadly address the needs of patients across the U.S.”
Actient was established in March 2009 in partnership with GTCR, one of the nation’s leading private equity firms.
About Actient Pharmaceuticals LLC
Actient Pharmaceuticals is a specialty products company focused on therapeutics to improve patient outcomes. The company was formed to acquire companies and products with a focus on select physician specialties. For more information, please visit www.actientpharma.com.
Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare and Information Services & Technology industries. The Chicago-based firm pioneered the “Leaders Strategy” – finding and partnering with world-class leaders as the critical first step in identifying, acquiring and building market-leading companies through acquisitions and organic growth. Since its inception, GTCR has invested more than $8.5 billion in over 200 companies. For more information, please visit www.gtcr.com.